Catherine Schulte
Stock Analyst at Baird
(4.21)
# 420
Out of 5,141 analysts
147
Total ratings
60%
Success rate
11.53%
Average return
Main Sectors:
Stocks Rated by Catherine Schulte
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GRAL GRAIL | Maintains: Outperform | $113 → $82 | $50.21 | +63.31% | 2 | Feb 20, 2026 | |
| TEM Tempus AI | Initiates: Outperform | $59 | $58.37 | +1.08% | 1 | Feb 17, 2026 | |
| GH Guardant Health | Initiates: Outperform | $120 | $103.10 | +16.39% | 1 | Feb 17, 2026 | |
| CAI Caris Life Sciences | Initiates: Outperform | $26 | $19.53 | +33.13% | 1 | Feb 17, 2026 | |
| A Agilent Technologies | Maintains: Outperform | $142 → $165 | $122.90 | +34.26% | 18 | Nov 25, 2025 | |
| EXAS Exact Sciences | Maintains: Outperform | $72 → $88 | $103.43 | -14.92% | 15 | Nov 4, 2025 | |
| AVTR Avantor | Maintains: Outperform | $15 → $17 | $9.03 | +88.26% | 14 | Oct 24, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,210 → $1,230 | $1,377.55 | -10.71% | 10 | Aug 4, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $553 → $567 | $510.93 | +10.97% | 28 | Jul 24, 2025 | |
| DHR Danaher | Maintains: Outperform | $226 → $229 | $209.50 | +9.31% | 11 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $2 | $3.10 | -35.48% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $41 | $48.57 | -15.69% | 4 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $88 → $68 | $57.52 | +18.22% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $29.21 | +30.09% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $33 | $48.59 | -32.08% | 3 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $335 → $281 | $117.67 | +138.80% | 7 | Sep 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $208 → $217 | $333.33 | -34.90% | 7 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $212.12 | -90.57% | 1 | Jun 28, 2018 |
GRAIL
Feb 20, 2026
Maintains: Outperform
Price Target: $113 → $82
Current: $50.21
Upside: +63.31%
Tempus AI
Feb 17, 2026
Initiates: Outperform
Price Target: $59
Current: $58.37
Upside: +1.08%
Guardant Health
Feb 17, 2026
Initiates: Outperform
Price Target: $120
Current: $103.10
Upside: +16.39%
Caris Life Sciences
Feb 17, 2026
Initiates: Outperform
Price Target: $26
Current: $19.53
Upside: +33.13%
Agilent Technologies
Nov 25, 2025
Maintains: Outperform
Price Target: $142 → $165
Current: $122.90
Upside: +34.26%
Exact Sciences
Nov 4, 2025
Maintains: Outperform
Price Target: $72 → $88
Current: $103.43
Upside: -14.92%
Avantor
Oct 24, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $9.03
Upside: +88.26%
Mettler-Toledo International
Aug 4, 2025
Maintains: Neutral
Price Target: $1,210 → $1,230
Current: $1,377.55
Upside: -10.71%
Thermo Fisher Scientific
Jul 24, 2025
Maintains: Outperform
Price Target: $553 → $567
Current: $510.93
Upside: +10.97%
Danaher
Jul 23, 2025
Maintains: Outperform
Price Target: $226 → $229
Current: $209.50
Upside: +9.31%
May 13, 2025
Maintains: Neutral
Price Target: $3 → $2
Current: $3.10
Upside: -35.48%
Apr 21, 2025
Maintains: Neutral
Price Target: $40 → $41
Current: $48.57
Upside: -15.69%
Feb 19, 2025
Downgrades: Neutral
Price Target: $88 → $68
Current: $57.52
Upside: +18.22%
Mar 1, 2023
Maintains: Outperform
Price Target: $42 → $38
Current: $29.21
Upside: +30.09%
Nov 21, 2022
Maintains: Outperform
Price Target: $56 → $33
Current: $48.59
Upside: -32.08%
Sep 22, 2020
Maintains: Neutral
Price Target: $335 → $281
Current: $117.67
Upside: +138.80%
Oct 30, 2019
Maintains: Neutral
Price Target: $208 → $217
Current: $333.33
Upside: -34.90%
Jun 28, 2018
Maintains: Outperform
Price Target: $17 → $20
Current: $212.12
Upside: -90.57%